Article Text


International variation in reported livebirth prevalence rates of Down syndrome, adjusted for maternal age


Reported livebirth prevalence of Down syndrome (DS) may be affected by the maternal age distribution of the population, completeness of ascertainment, accuracy of diagnosis, extent of selective prenatal termination of affected pregnancies, and as yet unidentified genetic and environmental factors. To search for evidence of the latter, we reviewed all published reports in which it was possible to adjust both for effects of maternal age and for selective termination (where relevant).

We constructed indices that allowed direct comparisons of prevalence rates after standardising for maternal age. Reference rates were derived from studies previously identified as having near complete ascertainment. An index value significantly different from 1 may result from random fluctuations, as well as from variations in the factors listed above. We found 49 population groups for which an index could be calculated. Methodological descriptions suggested that low values could often be attributed to underascertainment. A possible exception concerned African-American groups, though even among these most acceptable studies were compatible with an index value of 1. As we have reported elsewhere, there was also a suggestive increase in rates among US residents of Mexican or Central American origin. Nevertheless, our results suggest that “real” variation between population groups reported to date probably amounts to no more than ±25%. However, reliable data in many human populations are lacking including, surprisingly, some jurisdictions with relatively advanced health care systems. We suggest that future reports of DS livebirth prevalence should routinely present data that allow calculation of an index standardised for maternal age and adjusted for elective prenatal terminations.

  • Down syndrome
  • prenatal diagnosis
  • maternal age standardisation
  • epidemiology

Statistics from

Much information has been gathered world wide on the association of Down syndrome (DS) livebirth prevalence with maternal age.1 This has assumed increasing importance with the advent of prenatal screening, relying as it does on accurate maternal age specific rates to determine a mother’s risk of a DS livebirth.2 3 In spite of continuing searches for temporal, racial, geographical, and environmental differences in rates, the only such preconceptional predisposing factors to have been identified unambiguously, apart from maternal age itself, are the presence of a chromosome 21 translocation or of gonadal mosaicism for trisomy 21, and the existence of previously affected offspring. Increased rates have been reported in Jews of non-European origin in Israel,4 and in two different studies of Hispanics in California.5-7 Study of DS rates is complicated by the need to adjust for various potential sources of bias (see below).

In particular, the strength of the maternal age effect, involving a near 100-fold increase in risk between maternal ages of 15 and 45 years, makes it essential at least to adjust for differences in the maternal age distribution before making comparisons between populations.

One method for doing this is to construct maternal age adjusted indices, analogous to standardised rates used for comparing mortality and morbidity.8 These allow comparisons of prevalence between areas with widely differing maternal age related fertility patterns. We review here all published studies on DS rates world wide in which sufficient data are presented to allow a maternal age adjusted index to be derived. Our aim has been to derive an upper limit on the “real” variation between studied populations in age adjusted rates, rather than to obtain precise estimates for devising prenatal screening schedules applicable to specific populations. The latter aim, though necessary and worthwhile, cannot be done with currently available published data except for certain North American and European populations.1 9 Besides maternal age effects and “real” underlying variations, other factors that must be borne in mind when comparing rates include the following.

Completeness of ascertainment. Ideally, rates should be determined from cytogenetic examination of all or a representative sample of livebirths in a particular setting. Also, statistical precision requires a sample of well over 100 000 livebirths, much greater than currently available from all newborn cytogenetic studies combined, let alone those on which maternal age data are available. Systematic clinical examination with cytogenetic investigation of suspected cases may be almost as effective in achieving complete ascertainment, but, here too insufficient numbers are available from any single study. The great majority of studies, especially those involving over 100 000 livebirths, have abstracted diagnoses from two or more sources of already existing information, such as hospital and vital records, civil registers, reports from laboratories and so forth. These constitute overlapping incomplete lists, which can sometimes be used to estimate incompleteness of ascertainment.10 To date, only studies using birth certificates have attempted this.11 12 However, the completeness of reporting in these birth certificate studies has been so low (35 to 40%) that use of this approach necessarily introduces a large uncertainty into the derived rates.

Nevertheless, rates obtained in this manner, imperfect though the adjustment may be, have been appreciably higher than in many studies which ascertained a greater proportion of cases but in which an adjustment for completeness of reporting was not possible.13 Only one study provides data making it possible to infer that ascertainment has been essentially complete.14

Other studies, excluding those limited to birth certificates, are likely to underestimate rates because an adjustment for incomplete ascertainment cannot be made.

Accuracy of diagnosis. Unless all clinical diagnoses are confirmed cytogenetically, some non-DS cases may be included in error.

Even presumably astute clinicians may on rare occasions make a diagnosis later contradicted by cytogenetic study.15 Birth certificate reports abstracted by clerks from hospital records in the USA include 5 to 10% false positives.16 About half of these are readily detectable clerical errors in transcribing or coding diagnoses. The remainder result from mistaken medical judgements before newborn discharge from the hospital. These may well have been altered subsequently but not corrected on the original files. From these studies, a figure of 5 to 10% appears to be a plausible upper limit for the level of false positive diagnoses in the absence of cytogenetic confirmation.

The figure is unlikely to exceed 2-3% for studies using hospital newborn discharge records. In general, where diagnostic information is incomplete, any bias from false positive diagnoses is likely to be more than outweighed by underascertainment of cases.

Extent of prenatal screening. In many developed countries, prenatal diagnosis and selective termination of DS were introduced in the mid-1970s, and became widespread in the early 1980s. In some jurisdictions this has had a significant impact on observed livebirth prevalence rates.17 18 Adjustment must then be made for the numbers of electively terminated fetuses that would naturally have survived to birth.19 This requires that the numbers of prenatal terminations be reported separately from those of affected births.

Definition of base population. Ideally, rates should apply to the entire population, or to well defined subgroups, living within a specified geographical area. In practice, many studies are based on observations of births in maternity hospitals. In parts of the world where only a minority of mothers give birth in hospital, such rates may be biased by the very factors that determine where a baby is born. Most of these, such as social class, educational background, proximity, or convenience of transport etc, are not known to be associated with DS rates and are therefore probably of little consequence. However, an obvious potential source of overascertainment arises if mothers with complicated pregnancies are preferentially referred to centres of excellence in obstetrics.

Accuracy of reported ages and other demographic information. Accurate reporting of ages is required for the mothers both of affected cases and of unaffected births in the general population. Because of the relatively small numbers of births at the lower and upper extremes of maternal age, inaccuracies may lead to significant biases in these age groups.20 Also, incorrect reporting of the place of birth may lead to cases being wrongly included in or excluded from the study population.



Carothers8 reviewed three different methods for constructing maternal age adjusted indices and concluded that the most suitable for congenital abnormality rates involved indirect standardisation, analogous to the standardised mortality ratio (SMR). This index, referred to as BIISMA (“Birth Index Indirectly Standardised for Maternal Age”), compares the total number of DS births with the number expected if the maternal age specific rates derived from a reference population are applied to the study population. It is given by:

Embedded Image
whereb is the number of DS births, andni the total number of births at maternal age i, in the study population andRi is the reference rate at maternal age i.

Carothers8 pointed out that, under the assumption that the maternal age specific rates in the study population are a fixed multiple of the reference rates, BIISMA has the lowest standard error of the three indices considered, and is the easiest to adjust for underascertainment and for the effects of prenatal diagnosis. As can be seen from the formula, it requires only the maternal age distribution of all births, and the total number of DS births, in the study population. It does of course depend on the reference ratesR i, but this is of little relevance when comparing indices among themselves. In the small number of studies in which the maternal age distribution of all livebirths in the study population was not given, an alternative index, denoted BINSMA (“Birth Index Inversely Standardised for Maternal Age”), was used instead. It is given by:

Embedded Image
wheren is the total number of births, andb i the number of DS births at maternal age i, in the study population.

Carothers8 noted that, where sufficient data were available to compute both indices, they had closely similar values. We confine analysis to livebirths because of generally inadequate data on, and ambiguous definition of, stillbirths.15


From a search of the Science Citation Index and of the reference lists of earlier studies on DS prevalence, we have included, to the best of our knowledge, all published studies in which there were sufficient data to compute either index, and for which at least 10 000 total births were reported. Smaller studies would have been unlikely to include more than about 15 DS cases, and would have given estimates with such large standard errors as to be of little use.

The reference rates R i were taken from the “Derived rates” column of table II of the paper by Hecht and Hook,1 based on studies judged to have “near complete” ascertainment. Where indices were computed by five year maternal age groups, population data from England and Wales 1980 were used to apportion livebirths within each five year age group so as to determine the appropriate risk.21 When combined with the data from Hecht and Hook,1 these gave rate estimates for the age groups 15-19, 20-24, 25-29, 30-34, 35-39, 40-44, and 45-49 years of, respectively, 0.60, 0.71, 0.91, 1.54, 4.24, 16.22, and 53.3 per 1000 livebirths. These estimates are little affected by the choice of reference population since they depend only on the relative numbers of livebirths within each five year age group. The relevant formulae, and the conditions under which they produce unbiased estimates, are given by Carothers.8

The main category of study included here comprises those that made use of multiple sources of ascertainment or comprehensive cytogenetic registers or both in an attempt to identify all DS cases born, or diagnosed prenatally where relevant, in a well defined population. Such studies were confined to “developed” countries having relatively reliable record keeping within the health care system. A second major category comprises those based on maternities in particular hospitals. This is the only source of relevant data from parts of the world with less developed health care systems, though it also includes some studies from Europe and North America.

In addition there were a few surveys of DS cases living in a specified area, and two reviews of diagnostic information recorded on birth certificates. Such studies are clearly vulnerable to the possibility of underascertainment, though in some cases it is possible to adjust for this at the cost of introducing greater sampling variation (see above).

Finally, there were two complete cytogenetic surveys of all consecutive births in specified hospitals.22 23 Because these involved relatively small numbers, but otherwise used identical methods and referred to populations with a similar ethnic background, they were combined for the purpose of the present analysis. The above categorisation of studies is summarised in table 1.

Table 1

Summary of studies included in this report. The indices listed are those based on five year maternal age groups. Unless otherwise indicated in the ‘Notes’ column, they are of the indirectly standardised type (BIISMA). Also listed at the foot of the table, though not analysed in the text, are four studies that had data in common with more extensive data sets listed in the upper part of the table


Wherever possible, the indices have been computed for the age range 15-44 years. Higher and lower ages were excluded because they are often reported inaccurately (or not at all), and because the small absolute numbers of cases may have a disproportionate effect on the standard errors or biases of estimation or both. To allow for the possibility that the rates in each study population may not be the same multiple of those in the reference data at all maternal ages, we have also, where possible, computed separate indices for the age ranges 15-34 and 35-44. Where prenatal diagnosis has had a significant impact on crude livebirth prevalence rates, we adjusted the indices according to the formulae given by Carothers,8 using a multiplier (s) of 0.7 to allow for the proportion of electively aborted fetuses that would have survived naturally to term.19

In some studies, the numbers of pre- and postnatal cases were not reported separately, and for these it was therefore possible to compute the index only for the 15-34 age group in which we presumed that prenatal diagnosis had a negligible effect.

The majority of published studies report maternal ages only in quinquennial age groups, and for these the five year indices were computed by the formulae given by Carothers.8 Where single year maternal age data were available, both the one year and five year indices were calculated.

Two different classes of variation between estimated rates may be distinguished. First, there is “random” sampling variation arising from the finite size of the reported samples. Its magnitude can be estimated for each data set by standard formulae.8 The remaining “non-random” variation consists of several components as discussed above, including the “real” variation in which we are interested.

We can derive an upper limit for the latter by jointly estimating the non-random components. Our approach has been to derive the “James-Stein” estimator for each index. A very readable account of the method is given by Efron and Morris.24 The basic idea is to replace each index, y say, by a value,z, given by the equationz=y−f(y−ȳ), whereȳ is the global mean of all they− values and fis a constant known as the “shrinkage factor”.

If f is equal to zero, then thez− and y−values are identical. If f is 1, then they− values are replaced by the global mean. The essential feature of the James-Stein method is that the factorf is directly proportional to the sampling variation in y by the formula:

Embedded Image
where ς2 is the random sampling variation of y andk is the number of indices being estimated. Thus, if y is poorly estimated then ς2 is large, f is close to unity, and the effect is to “shrink” ytowards the global mean. Conversely, if y is accurately estimated then ς2 is small,f is close to zero, and the effect is to leave y almost unchanged. James and Stein showed that, provided that k>3, this procedure leads to a set of estimates that have lower expected mean squared error than the original ones and that therefore give better estimates of their non-random variation.


A total of 36 studies, covering 49 population groupings, satisfied the inclusion criteria. Approximately 35 further studies gave raw estimates of livebirth prevalence of DS, but either based on fewer than 10 000 total births or lacking sufficient information to allow adjustment for maternal age. Comparison of one year and five year indices in 17 groupings where both could be calculated showed that on average the five year index exceeded the one year index by only 0.006 (SE 0.011).

Similarly, in the 40 cases where indices for both younger and older mothers could be computed, the former exceeded the latter by a mean of only 0.015 (SE 0.014). Since these differences are trivial in relation to other sources of variation, further analysis was confined to the five year indices and to the full (15-44 years) maternal age range.

Principal characteristics of the groupings, together with their five year indices, are summarised in table 1. Indices are presented graphically in fig 1.

Figure 1

Plot of maternal age standardised indices listed in table 1. Values plotted are those based on maternal ages 15-44 years, where available, and on the younger age group (15-34 years) otherwise. Intervals represent 1 SE. James-Stein estimators are represented by asterisks. “Near complete” studies, all of European origin, are those contributing to the baseline rates estimated by Hecht and Hook.1


Examination of table 1 and fig 1 shows two exceptionally low indices from groups with a predominantly European ancestral background. These were from the studies of Uchida,29 which was based on a survey of living DS cases and therefore likely to have missed early neonatal deaths, and of Stark and White,33 which missed cases not indicated on birth certificates and those not in contact with the institutions surveyed. Both were therefore likely to have been seriously underascertained. The remaining 25 indices varied from 0.76 to 1.77 with a weighted mean of 0.923 (SE 0.009).

The exceptionally high value of 1.77 from a Croation study was associated with a large standard error.48 The James-Stein method “shrank” this value to less than 1, suggesting that it is a random outlier.


Two indices from the groups with predominantly African (mainly West African) ancestry were exceptionally low. One was from the study of Stark and White33 referred to above. The other, from Little et al,49 is somewhat puzzling, since the indices obtained from other ethnic groups in the same study were more closely comparable with those obtained elsewhere. Thus we cannot rule out the possibility of a genuinely low rate among Afro-Americans within the community served by the hospitals included in this study. Nevertheless, the index is so far out of line with those obtained from other groups of African ancestry that we are inclined to suspect underascertainment. Excluding these two studies, the range of values obtained from the remaining six groups of African ancestry was from 0.84 to 1.00 with a weighted mean of 0.911 (SE 0.043).


There were three indices from recent migrant groups living in the USA of central American, mainly Mexican, origin with a range from 0.73 to 1.30 and a weighted mean of 1.180 (SE 0.043). Because the mean is significantly greater than 1, whereas any biases would be expected to be in the direction of lower ascertainment in these groups, this may be considered evidence that they have a higher real rate of DS, as we have discussed elsewhere.7


Indices were obtained from 10 other groups that could not be categorised as above, and in which there were individually insufficient data to enable us to make useful comparisons. One high value from a study of Israeli Jews of non-European origin may indicate a higher real rate in this group, as noted by the original authors.4 On the other hand, the lowest rate came from Israeli Jews of heterogeneous origin. However, this was an early study based on notifications of congenital abnormalities, and is therefore likely to have been underascertained.27


Excluding the five studies noted above for which there were grounds to suspect serious underascertainment, the mean James-Stein estimator of the remaining 43 values was 0.964 (SD 0.094) with a range from 0.76 to 1.26. The mean values for groups of European, African, Latin-American, and other ancestry were respectively 0.95 (SD 0.07), 0.95 (SD 0.05), 1.09 (SD 0.22), and 0.97 (SD 0.11).


If it is legitimate to ignore the five outliers mentioned above, then we can conclude that underlying variation between groups studied to date is no greater than ±25% around the global mean. Furthermore, in view of the many sources of ascertainment variation to which most of these studies are subject, the totality of published data could well be consistent with no real variation at all, and might explain why a search for environmental factors associated with Down syndrome has been so unproductive. Nevertheless, the high rate among those of Mexican or Central American origin in the USA is probably real, and the possibility cannot be excluded of consistent differences in other groups not yet studied extensively.

In fact, the number of ethnic groupings for which there are useful data is rather small. It is not surprising, in view of other health related priorities in the less developed world, that we were able to find little or no usable data from the Indian subcontinent, China, Africa, and Latin America. However, we were also not able to identify any studies satisfying our criteria from several areas with advanced health care systems, in particular Japan and certain Arabic-speaking countries.

Also, the broad racial groupings we have used are necessarily rather crude and may conceal considerable differences. Thus, populations of European origin include not only those from Europe itself, but also some from North America and Australia, those of African origin include both native Africans and Afro-Americans, and those of Latin-American origin include Spanish speaking populations of diverse ethnic origins. Studies of the latter have so far been confined exclusively to residents of the western USA and have not, for example, included any of Puerto Rican origin. Finally, even from parts of the world with well developed health care systems there have been woefully few studies that could be considered relatively free from bias. We would define the necessary requirements for such studies as: complete ascertainment of prenatally diagnosed cases within the jurisdiction of livebirths under study; extensive ascertainment of livebirths from multiple sources; cytogenetic or detailed phenotypic diagnostic confirmation; reliable data on maternal ages; reliable data on the fate of prenatally diagnosed cases; and a clearly defined reference population.

The only studies approaching this ideal have been from populations of European origin and provided the baseline estimates used in the present analysis.1 9 There clearly remains a need for unbiased rate estimates from other ethnic groups. The use of indices standardised for maternal age is a simple and easily understood way to compare rates in populations with widely differing maternal age distributions. We suggest that future reports of DS livebirth prevalence should, wherever possible, present data in a form that allows calculation of such an index using the reference rates quoted above, and that also allows adjustment for elective terminations following prenatal diagnosis. The latter will become increasingly essential as prenatal diagnosis of DS becomes more widespread and effective.


We thank Elizabeth Daniels for bibliographical assistance in the early phases of the study, which was supported in part by Grant No LM04996 from the National Library of Medicine, US National Institutes of Health.


View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.